Internal Medicine · Fayetteville, AR
NPI
1093741910
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
3344 N Futrall Dr
Fayetteville, AR, 72703
Phone (479) 521-8200
Groups this clinician bills Medicare through
Medicare paid, 2024
$133K
13,578 services
Medicare patients, 2024
652
Average age 75
Drug cost, 2024
$1.4M
12,914 prescriptions
Company payments, 2025
$548
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David W Clay was code Q9967 (low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml), 3,675 times for 36 patients. In total David W Clay billed 13,578 services in 166 codes, and Medicare paid $133K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-27.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 3,675 | 36 | $0.10 | $372 |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 2,120 | 13 | $0.09 | $190 |
| 99213 Office E&M - Established | Office | 747 | 345 | $39.94 | $30K |
| 36415 Venipuncture Blood Collection | Office | 665 | 447 | $8.63 | $5,736 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 601 | 320 | $11.42 | $6,865 |
| 80053 Clinical Chemistry | Office | 500 | 402 | $10.33 | $5,164 |
| 85025 Blood Count | Office | 485 | 401 | $7.60 | $3,685 |
| 99214 Office E&M - Established | Office | 451 | 371 | $34.76 | $16K |
| 80061 Clinical Chemistry | Office | 369 | 326 | $13.12 | $4,841 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 277 | 277 | $30.16 | $8,353 |
| 83036 Blood Count | Office | 223 | 140 | $9.49 | $2,115 |
| 84443 Clinical Chemistry | Office | 210 | 179 | $16.41 | $3,447 |
| 81001 Clinical Chemistry | Office | 169 | 150 | $3.10 | $523 |
| 82306 Clinical Chemistry | Office | 91 | 88 | $28.79 | $2,620 |
| 82570 Clinical Chemistry | Office | 71 | 58 | $5.08 | $361 |
By year: 2022 $156K for 12,683 services; 2023 $153K for 11,523 services; 2024 $133K for 13,578 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 665 | 447 | $8.63 | $5,736 |
| 80053 Clinical Chemistry | 500 | 402 | $10.33 | $5,164 |
| 85025 Blood Count | 485 | 401 | $7.60 | $3,685 |
| 80061 Clinical Chemistry | 369 | 326 | $13.12 | $4,841 |
| 83036 Blood Count | 223 | 140 | $9.49 | $2,115 |
| 84443 Clinical Chemistry | 210 | 179 | $16.41 | $3,447 |
| 81001 Clinical Chemistry | 169 | 150 | $3.10 | $523 |
| 82306 Clinical Chemistry | 91 | 88 | $28.79 | $2,620 |
| 82570 Clinical Chemistry | 71 | 58 | $5.08 | $361 |
| 82043 Clinical Chemistry | 70 | 57 | $5.66 | $396 |
Medicare prescription drug claims, 2024
In 2024, the drug David W Clay prescribed most often to Medicare patients was Levothyroxine Sodium, with 638 prescriptions and refills. In total David W Clay wrote 12,914 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 638 | 1,320 | 123 | $5,899 |
| Atorvastatin Calcium Generic | 603 | 1,352 | 138 | $4,748 |
| Lisinopril Generic | 532 | 1,082 | 105 | $2,483 |
| Amlodipine Besylate Generic | 485 | 1,058 | 106 | $2,204 |
| Metformin Hcl Generic | 413 | 840 | 84 | $5,003 |
| Omeprazole Generic | 336 | 736 | 81 | $3,154 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 310 | 310 | 68 | $5,607 |
| Citalopram Hbr Citalopram Hydrobromide | 273 | 498 | 52 | $1,302 |
| Clonazepam Generic | 249 | 286 | 43 | $1,363 |
| Hydrochlorothiazide Generic | 229 | 510 | 51 | $528 |
| Gabapentin Generic | 224 | 357 | 49 | $2,829 |
| Eliquis Apixaban | 213 | 301 | 31 | $170K |
| Pravastatin Sodium Generic | 205 | 460 | 45 | $2,548 |
| Losartan Potassium Generic | 203 | 524 | 54 | $1,887 |
| Valsartan Generic | 199 | 415 | 44 | $6,376 |
Brand drugs: 1,793 claims; generic drugs: 11,059 claims; opioid claims: 494.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David W Clay $548 ($548 in general payments such as food, travel and fees) from 11 companies. The largest payer was Pfizer Inc. with $169.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 17 | $169 |
| Abbvie Inc. ABBV | 4 | $95.13 |
| Grifols USA, LLC | 4 | $71.8 |
| Genzyme Corporation SNY | 3 | $53.82 |
| Amgen Inc. AMGN | 2 | $29.05 |
| Lilly USA, LLC LLY | 2 | $28.97 |
| CSL Behring CSL.AX | 1 | $25.9 |
| ANI Pharmaceuticals, Inc. ANIP | 1 | $22.87 |
| Actelion Pharmaceuticals US, Inc. JNJ | 1 | $22.22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $14.66 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.